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INTRODUCTION
Narcolepsy is defined as a pentad of symptoms that
include excessive daytime sleepiness, disturbed nocturnal
sleep, sleep paralysis, cataplexy, and hypnagogic or
hypnopompic hallucinations (1). The cause of narcolepsy
is still unknown, although it has been associated with a
combination of genetic and environmental factors; the
prevalence is approximately 0.04% (2). The peak age of
onset is the second decade of life, and onset after age 55 or
prior to age 10 is rare. Not every symptom is present in all
patients, and the severity is also variable (2).
Hypocretin, a neuropeptide of hypothalamic origin, has
been involved in the pathogenesis of narcolepsy. The CSF
hypocretin-1 levels are very low or even undetectable in
most narcoleptic patients with cataplexy. The HLA-
DQB1*0602 allele, which is involved in the control of the
hypocretin receptor, is also present in 88% to 98% of such
patients (2).
The association between narcolepsy and vaccination
against the 2009 pandemic influenza A (H1N1) virus was
initially suggested in 2010 in Finland and Sweden, leading
to the suspension of vaccination in these countries (3).
Additional cases were subsequently reported (4-5).
Herein, we describe a patient with narcolepsy with
cataplexy syndrome after A/H1N1 vaccination in Brazil
and discuss the potential causes and treatment.
CASE REPORT
A 19-year-old woman, first observed in May 2010, 40 days
after being vaccinated against the 2009 pandemic influenza A
(H1N1) virus (Arepanrix
TM - Lot A80CA254A), complained
of acute and intense headache. Physical examination and
general blood tests were unremarkable. A few days later, she
presented with uncontrollable sleep attacks, a sensation of
‘‘dreaming with open eyes’’, nightmares, and a poor quality
of sleep. An electroencephalogram, an MRI of the skull, and
thyroid laboratory test results were all found to be normal.
She gained 9 kg (19.8 lbs) in two months. In September, she
presented with cataplexy, hypophonia, and weakness in all
limbs without falls. In February 2011, she experienced an
episode of sleep paralysis but no hypnagogic hallucinations.
The results of a neurological examination were normal.
The patient scored 19 points on the Epworth Somnolence
Scale. Polysomnography disclosed a sleep efficiency of
81.8% and a sleep latency of three minutes. She did not
display apnea/hypopnea but had a Respiratory Effort
Related Arousal (RERA) index of 72, which was normalized
with nasal Continuous Positive Airway Pressure (CPAP)
(8 cm H2O). She subsequently presented with very stable
sleep. The multiple sleep latency test, performed one week
after the introduction of nasal CPAP to avoid false-positive
results, revealed sleep latencies between 1 and 6.5 minutes,
and three sleep onset rapid eye movement periods
(SOREMPs) lasting from 8 to 12 minutes. Notably, the
patient carries the HLA-DQB1* 06:02 allele. The CSF
hypocretin level could not be determined because the test
was not available in the state of Minas Gerais.
Based on the overall clinical findings and on the results
from the ancillary tests, a diagnosis of narcolepsy was made
(6). Appropriate communication to the public service for
pharmacological vigilance and to the company responsible
for the production of the vaccine were first undertaken on
September 30, 2010. The patient was treated with modafinil
(200 mg/day) for hypersomnolence and venlafaxine
(37.5 mg/day) for cataplexy. This approach to treatment
achieved an excellent clinical response.
DISCUSSION
There is some evidence that narcolepsy is an autoimmune
disorder or involves an infectious agent with participation
of the immune system (7-8). Cases of narcolepsy after 2009
pandemic influenza A (H1N1) virus vaccination have been
described in Sweden, Finland, Canada, France, and the
United States (3). The diagnosis was defined by the
association of hypersomnolence, cataplexy, presence of the
HLA DQB1*0602 allele, a positive multiple sleep latency test
for narcolepsy, and low CSF hypocretin levels. By January
2011, 162 patients vaccinated with Arepanrix
TM presenting
narcolepsy were reported to GlaxoSmithKline (5).
Reported cases experienced an onset of symptoms
ranging from two days to five months (usually two to
eight weeks) after vaccination, intense and unusual
hypersomnolence, cataplexy, rapid weight gain, and
atypical age for narcolepsy. Most cases received vaccines
with ASO3 as an adjuvant (Arepanrix
TM and Are-
panrix
TM), which are associated with stronger immune
responses, and not with Panenza
TM. An association
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77between narcolepsy, streptococcal infection and A/H1N1
influenza has also been reported (3). Putative mechanisms
include trigger of a specific immune response to A/H1N1
followed by molecular mimicry or generalized stimulation
of the immune system (3). The WHO Independent Global
Advisory Committee on Vaccine Safety reported no
increased risk of narcolepsy associated with the use of
any vaccine in the past (5).
The presented case occurred after A/H1N1 vaccination
with ASO3. The clinical and neurophysiologic features, plus
the HLA genotype, even without CSF hypocretin data, fulfill
the diagnosis of narcolepsy, according to the recently
published Brazilian guidelines (6). Such guidelines state
that the determination of CSF hypocretin levels is manda-
tory only in cases of narcolepsy without cataplexy or in
patients with negative multiple sleep latency test results.
Considering the temporal association between the vaccina-
tion and the emergence of the clinical symptoms, there may
be a link with the vaccine. Interestingly, however, our
patient presented with cataplexy (hypocretin receptor-2
knockout) without fragmented sleep patterns (no hypocre-
tin receptor-1 knockout), suggesting a link between recep-
tor-2 and susceptibility to this vaccine.
Post-vaccine narcolepsy may be less rare than previously
thought. Diagnosis in the early stages would allow for the
use of certain treatment options such as immunosuppres-
sors that may be able to arrest or at least delay hypocretin
cell loss (8), and/or the use of the usual stimulant and
antidepressant drugs.
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